Fraser Murray

About

Fraser Murray is a drug discovery specialist and entrepreneur with nearly 30 years of experience in early drug development across pharma and biotech. In addition to serving as Head of Scientific Evaluation at Advent Life Sciences, he is CEO of portfolio company Pheno Therapeutics, and previously led Pandeia Therapeutics (acquired in December 2022), Chronos Therapeutics, and Polleo Pharma. He began his career at Merck's Neuroscience Research Centre and held roles at AstraZeneca and Shire; he studied Immunology and Pharmacology at the University of Strathclyde, earned a PhD in Neuropharmacology at the University of London, and completed an executive MBA at Alliance Manchester Business School.